Nelitolimod
Phase 1Small molecule
Nelitolimod is one of 11 small molecule programs targeting Liver Metastases. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Liver Metastases
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 2
Avastin
RochePhase 2
Camptosar
PfizerPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
5-Fluorouracil
Merck & Co.Phase 2
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 2
Anti-CEA CAR-T Cells
SSorrento Therapeutics, Inc.
Phase 1
Definity
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nelitolimod. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNorthwell Health